Contact our Novo Nordisk Investor Relations team
Novo Nordisk Up After Strong Q3 Results; Raises Outlook - TipRanks.com
Novo Nordisk: A Long-Term Hold Even At Current Valuations (NYSE:NVO) | Seeking Alpha
Contact our Novo Nordisk Investor Relations team
image_001.jpg
Novo Nordisk - Class B Shares (NOVO B) Dividends
Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates | Nasdaq
Novo Nordisk CEO confident US obesity drug supply issues fixed by H2'22 | S&P Global Market Intelligence
NOVO NORDISK A S - NVO / Novo-Nordisk A/S 6-K - Current Report of Foreign Issuer - FORM 6-K - 6-K - February 21, 2020
f6k_01.jpg
Novo Nordisk And COVID-19: As If Nothing Happened (OTCMKTS:NONOF) | Seeking Alpha
Annual Report 2007 - Novo Nordisk
Novo Nordisk (NVO) Investor Presentation - Slideshow (NYSE:NVO) | Seeking Alpha
Novo Nordisk (NVO) Q4 Earnings Beat Estimates, Revenues Miss | Nasdaq
Novo Nordisk A/S 2022 Q4 - Results - Earnings Call Presentation (NYSE:NVO) | Seeking Alpha
Investor highlights - Get an overview of our investor services
Novo Nordisk: Why I'm Buying This Diabetes Giant Despite The High P/E (NYSE:NVO) | Seeking Alpha
Current Novo Nordisk dividend in March 2023
Novo Nordisk Annual General Meeting 2022
Novo Nordisk A/S 2022 Q2 - Results - Earnings Call Presentation (NYSE:NVO) | Seeking Alpha
![Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States](https://photos.prnewswire.com/prnfull/20150421/200097LOGO "Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States")
Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States
Contact our Novo Nordisk Investor Relations team
Novo Nordisk snaps up Dicerna for $3.3B, 2 years after liver research deal | S&P Global Market Intelligence
